A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

May 12, 2026

Study Completion Date

May 12, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

TNB-383B

Intravenous (IV) Injection

Trial Locations (14)

20246

Universitaetsklinikum Hamburg-Eppendorf /ID# 239636, Hamburg

27157

Wake Forest Univ HS /ID# 238787, Winston-Salem

27514

University of North Carolina /ID# 238685, Chapel Hill

28204

Levine Cancer Institute /ID# 238786, Charlotte

48149

Duplicate_Universitaetsklinikum Muenster /ID# 239637, Münster

50937

Universitaetsklinikum Koeln /ID# 239676, Cologne

53226

Wisconsin Medical Center /ID# 238684, Milwaukee

63110

Washington University-School of Medicine /ID# 238681, St Louis

70112

Tulane University School of Medicine /ID# 242322, New Orleans

94143

University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680, San Francisco

55905-0001

Mayo Clinic - Rochester /ID# 238683, Rochester

10029-6542

Mt Sinai /ID# 242317, New York

10065-6007

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 244831, New York

01307

Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 239638, Dresden

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

TeneoOne Inc.

INDUSTRY